Analysis of predictive and prognostic soluble biomarkers in advanced non-small cell lung cancer (NSCLC) patients treated with anti-PD1/PDL1

被引：0

作者：

Gallach Garcia, S. ^{[1
]}

Garde Noguera, J. ^{[2
]}

Torres Martinez, S. ^{[1
]}

Aparisi Aparisi, F. D. A. ^{[3
]}

Vidal Martinez, J. ^{[4
]}

Escorihuela, E. ^{[5
]}

Gisbert Criado, R. ^{[4
]}

Moreno, A. ^{[5
]}

Ferrero Gimeno, M. ^{[5
]}

Meri Abad, M. ^{[3
]}

Shaheen, I. ^{[3
]}

Calabuig-Farinas, S. ^{[6
]}

Blasco Cordellat, A. ^{[7
]}

Honrubia Peris, B. ^{[2
]}

Garcia Sanchez, J. ^{[2
]}

Jantus Lewintre, E. ^{[8
]}

Camps, C. ^{[9
]}

机构：

[1] FIHGUV Fdn Invest Hosp Gen Univ Valencia, Unidad Mixta TRIAL CIPF FIHGUV, CIBERONC, Mol Oncol Lab, Valencia, Spain

[2] Hosp Arnau Vilanova, Med Oncol, Valencia, Spain

[3] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain

[4] Hosp Arnau Vilanova, Dept Clin Anal, Valencia, Spain

[5] FIHGUV Fdn Invest Hosp Gen Univ Valencia, Unidad Mixta TRIAL CIPF FIHGUV, Mol Oncol Lab, Valencia, Spain

[6] Univ Valencia, FIHGUV Fdn Invest Hosp Gen Univ Valencia, Unidad Mixta TRIAL CIPF FIHGUV, Dept Pathol,Mol Oncol, Valencia, Spain

[7] Hosp Gen Univ Valencia, CIBER ONC, Med Oncol, Valencia, Spain

[8] Univ Politecn Valencia, FIHGUV Fdn Invest Hosp Gen Univ Valencia, Unidad Mixta TRIAL CIPF FIHGUV, Dept Biotechnol,CIBERONC,Mol Oncol, Valencia, Spain

[9] Univ Valencia, Fdn Invest Hosp Gen Univ Valencia, Unidad Mixta TRIAL CIPF FIHGUV, Med Oncol,Hosp Gen Univ Valencia,CIBERONC,Dept Me, Valencia, Spain

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.1159

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1039P

引用

页码：S714 / S714

页数：1

共 50 条

[1] Hepcidin expression as a predictive biomarker for anti-PD1/PDL1 antibody monotherapy for advanced non-small cell lung cancer
Yamamoto, M.
Kubo, S.
Hirama, N.
Teranishi, S.
Tashiro, K.
Seki, K.
Maeda, C.
Hiro, S.
Kajita, Y.
Sugimoto, C.
Segawa, W.
Nagayama, H.
Nagaoka, S.
Kudo, M.
Kaneko, T.
[J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1049 - S1050
[2] Soluble immune biomarkers to anti-PD1 treatment in non-small cell lung cancer (NSCLC)
Garde-Noguera, J.
Jantus-Lewintre, E.
Honrubia Peris, B.
Gallach Garcia, S.
Zhang, F.
Garcia Sanchez, J.
Calabuig Farinas, S.
Blasco Cordellat, A.
Piera Molons, N.
Vidal-Martinez, J.
Murado-Pardo, J.
Condori Farfan, L. D.
Gisbert-Criado, R.
Escorihuela, E.
Camps, C.
[J]. ANNALS OF ONCOLOGY, 2018, 29
[3] Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Yamamoto, M.
Hirama, N.
Teranishi, S.
Tashiro, K.
Kubo, S.
Kudo, M.
Kaneko, T.
[J]. ANNALS OF ONCOLOGY, 2023, 34
[4] Soluble biomarker signature to predict outcome of patients with non-small-cell lung cancer (NSCLC) treated with anti-PD1/PDL1 monoclonal antibodies.
Garde-Noguera, Javier
Jantus-Lewintre, Eloisa
Gallach, Sandra
Vidal-Martinez, Jose
Blasco, Ana
Garcia Sanchez, Jose
Zhang, Feiyu
Aparisi, Francisco
Honrubia Peris, Beatriz
Condori Farfan, Lauren
Torres Martinez, Susana
Piera Molons, Nuria
Murado-Pardo, J.
Gisbert-Criado, R.
Calabuig-Farinas, Silvia
Camps, Carlos
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[5] Clinical analysis of patients (pts) with lung cancer treated with anti-PD1/PDL1 therapy
Zhao, Xin
Liu, Siyao
Su, Junyan
[J]. CANCER RESEARCH, 2023, 83 (07)
[6] INCIDENCE AND GRADE OF PNEUMONITIS IN ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED WITH ANTI-PD1 ANTIBODIES
Yam, A. O.
Mersiadis, A.
Gao, B.
Hui, R.
Nagrial, A.
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 71 - 72
[7] Exploratory analysis of factors associated with hyperprogression in advanced non-small cell lung cancer (NSCLC) treated with PD1/PDL1 inhibitors.
Decatris, Marios P.
Thomas, Joy A.
Hayes, Mark
Ryan, Philip
Phillips, Aled
ElBatrawy, Sherouk
Bowden, Caitlin
Du Rand, Ingrid
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[8] The prognostic impact of PD1 and PDL1 expression in non-small cell lung cancer
Schmidt, Lars Henning
Kuemmel, Andreas
Goerlich, Dennis
Mohr, Michael
Broeckling, Sebastian
Gruenewald, Inga
Wardelmann, Eva
Schultheis, Anne
Mikesch, Jan-Henrik
Vietmeier, Benedikt
Mueller-Tidow, Carsten
Marra, Alessandro
Schliemann, Christoph
Berdel, Wofgang E.
Hartmann, Wolfgang
Rainer, Wiewrodt
[J]. EUROPEAN RESPIRATORY JOURNAL, 2015, 46
[9] Clinical analysis of patients (pts) with Lung cancer treated with anti-PD1/PDL1 therapy.
Tian, Kaihua
Wang, Xintong
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[10] A single centre experience of anti-PDL1 and anti-PD1 agents in treatment of non-small cell lung cancer (NSCLC)
Saunders, E.
Rubasingham, J.
Muthukumar, D.
Ingle, C.
[J]. LUNG CANCER, 2019, 127 : S44 - S44

← 1 2 3 4 5 →